- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 794172, 9 pages
Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
Received 30 April 2011; Revised 5 August 2011; Accepted 5 August 2011
Academic Editor: Kalpna Gupta
Copyright © 2012 Una Adamcic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- U. Emmenegger, S. Man, Y. Shaked et al., “A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens,” Cancer Research, vol. 64, no. 11, pp. 3994–4000, 2004.
- M. Colleoni, L. Orlando, G. Sanna et al., “Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects,” Annals of Oncology, vol. 17, no. 2, pp. 232–238, 2006.
- K. Garber, “Could less be more? Low-dose chemotherapy goes on trial,” Journal of the National Cancer Institute, vol. 94, no. 2, pp. 82–84, 2002.
- T. Browder, C. E. Butterfield, B. M. Kräling et al., “Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer,” Cancer Research, vol. 60, no. 7, pp. 1878–1886, 2000.
- L. G. Daenen, Y. Shaked, S. Man et al., “Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models,” Molecular Cancer Therapeutics, vol. 8, no. 10, pp. 2872–2881, 2009.
- Y. Hamano, H. Sugimoto, M. A. Soubasakos et al., “Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression,” Cancer Research, vol. 64, no. 5, pp. 1570–1574, 2004.
- G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel, “Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12917–12922, 2003.
- J. S. De Jong, P. J. Van Diest, P. Van Der Valk, and J. P. A. Baak, “Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops,” Journal of Pathology, vol. 184, no. 1, pp. 44–52, 1998.
- G. Gasparini, “Metronomic scheduling: the future of chemotherapy?” The Lancet Oncology, vol. 2, no. 12, pp. 733–740, 2001.
- G. Klement, S. Baruchel, J. Rak et al., “Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity,” Journal of Clinical Investigation, vol. 105, no. 8, pp. R15–R24, 2000.
- A. L. Wong, Z. A. Haroon, S. Werner, M. W. Dewhirst, C. S. Greenberg, and K. G. Peters, “Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues,” Circulation Research, vol. 81, no. 4, pp. 567–574, 1997.
- K. E. Fathers, C. M. Stone, K. Minhas et al., “Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy,” The American Journal of Pathology, vol. 167, no. 6, pp. 1753–1762, 2005.
- M. Hockel and P. Vaupel, “Biological consequences of tumor hypoxia,” Seminars in Oncology, vol. 28, pp. 36–41, 2001.
- P. Vaupel, D. K. Kelleher, and M. Hockel, “Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy,” Seminars in Oncology, vol. 28, pp. 29–35, 2001.
- R. A. Gatenby and R. J. Gillies, “Why do cancers have high aerobic glycolysis?” Nature Reviews Cancer, vol. 4, no. 11, pp. 891–899, 2004.
- A. Das, W. Fanslow, D. Cerretti, E. Warren, N. Talarico, and P. McGuire, “Angiopoietin/Tek interactions regulate mmp-9 expression and retinal neovascularization,” Laboratory Investigation, vol. 83, no. 11, pp. 1637–1645, 2003.
- J. Folkman, “Angiogenesis,” Annual Review of Medicine, vol. 57, pp. 1–18, 2006.
- R. S. Bhatt, J. Merchan, R. Parker et al., “A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma,” Cancer, vol. 116, no. 7, pp. 1751–1756, 2010.
- D. G. Perez, V. J. Suman, T. R. Fitch et al., “Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A,” Cancer, vol. 115, no. 1, pp. 119–127, 2009.
- K. A. Varker, J. E. Biber, C. Kefauver et al., “A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma,” Annals of Surgical Oncology, vol. 14, no. 8, pp. 2367–2376, 2007.
- J. L. Brown, Z. A. Cao, M. Pinzon-Ortiz et al., “A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 145–156, 2010.
- S. Dellapasqua, F. Bertolini, V. Bagnardi et al., “Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer,” Journal of Clinical Oncology, vol. 26, no. 30, pp. 4899–4905, 2008.
- U. Rodeck, M. Herlyn, H. D. Menssen, R. W. Furlanetto, and H. Koprowski, “Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors,” International Journal of Cancer, vol. 40, no. 5, pp. 687–690, 1987.
- P. Mombaerts, J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. Papaioannou, “RAG-1-deficient mice have no mature B and T lymphocytes,” Cell, vol. 68, no. 5, pp. 869–877, 1992.
- G. J. Guillemin and B. J. Brew, “Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 388–397, 2004.
- E. M. Bridges and A. L. Harris, “The angiogenic process as a therapeutic target in cancer,” Biochemical Pharmacology, vol. 81, pp. 1183–1191, 2011.
- M. I. Lin and W. C. Sessa, “Antiangiogenic therapy: creating a unique “window” of opportunity,” Cancer Cell, vol. 6, no. 6, pp. 529–531, 2004.
- P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000.
- S. B. Coffelt, C. E. Lewis, L. Naldini, J. M. Brown, N. Ferrara, and M. De Palma, “Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors,” The American Journal of Pathology, vol. 176, no. 4, pp. 1564–1576, 2010.
- M. Hangai, Y. S. Moon, N. Kitaya et al., “Systemically expressed soluble Tie2 inhibits intraocular neovascularization,” Human Gene Therapy, vol. 12, no. 10, pp. 1311–1321, 2001.
- P. Lin, P. Polverini, M. Dewhirst, S. Shan, P. S. Rao, and K. Peters, “Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth,” Journal of Clinical Investigation, vol. 100, no. 8, pp. 2072–2078, 1997.
- K. G. Peters, C. D. Kontos, P. C. Lin et al., “Functional significance of Tie2 signaling in the adult vasculature,” Recent Progress in Hormone Research, vol. 59, pp. 51–71, 2004.
- P. Lin, J. A. Buxton, A. Acheson et al., “Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8829–8834, 1998.
- G. Siemeister, M. Schirner, K. Weindel et al., “Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway,” Cancer Research, vol. 59, no. 13, pp. 3185–3191, 1999.
- A. Stratmann, T. Acker, A. M. Burger, K. Amann, W. Risau, and K. H. Plate, “Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants,” International Journal of Cancer, vol. 91, no. 3, pp. 273–282, 2001.
- S. Tanaka, K. Sugimachi, Y. I. Yamashita et al., “Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma,” Hepatology, vol. 35, no. 4, pp. 861–867, 2002.
- F. Bertolini, S. Paul, P. Mancuso et al., “Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells,” Cancer Research, vol. 63, no. 15, pp. 4342–4346, 2003.
- J. L. Yu, J. W. Rak, P. Carmeliet, A. Nagy, R. S. Kerbel, and B. L. Coomber, “Heterogeneous vascular dependence of tumor cell populations,” The American Journal of Pathology, vol. 158, no. 4, pp. 1325–1334, 2001.
- P. V. Dickson, J. B. Hamner, T. L. Sims et al., “Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy,” Clinical Cancer Research, vol. 13, no. 13, pp. 3942–3950, 2007.
- S. Song, A. J. Ewald, W. Stallcup, Z. Werb, and G. Bergers, “PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival,” Nature Cell Biology, vol. 7, no. 9, pp. 870–879, 2005.
- Y. Hasumi, A. Klosowska-Wardega, M. Furuhashi, A. Östman, C. H. Heldin, and C. Hellberg, “Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling,” International Journal of Cancer, vol. 121, no. 12, pp. 2606–2614, 2007.
- R. Harfouche and S. N. A. Hussain, “Signaling and regulation of endothelial cell survival by angiopoietin-2,” The American Journal of Physiology, vol. 291, no. 4, pp. H1635–H1645, 2006.
- I. B. Lobov, P. C. Brooks, and R. A. Lang, “Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11205–11210, 2002.
- K. Teichert-Kuliszewska, P. C. Maisonpierre, N. Jones et al., “Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2,” Cardiovascular Research, vol. 49, no. 3, pp. 659–670, 2001.
- P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis,” Science, vol. 277, no. 5322, pp. 55–60, 1997.
- L. Eklund and B. R. Olsen, “Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling,” Experimental Cell Research, vol. 312, no. 5, pp. 630–641, 2006.
- H. T. Yuan, E. V. Khankin, S. A. Karumanchi, and S. M. Parikh, “Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 2011–2022, 2009.
- R. S. Kerbel, J. Yu, J. Tran et al., “Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches,” Cancer and Metastasis Reviews, vol. 20, no. 1-2, pp. 79–86, 2001.
- G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, “Vascular-specific growth factors and blood vessel formation,” Nature, vol. 407, no. 6801, pp. 242–248, 2000.
- J. A. Garcia-Saenz, M. Martin, A. Calles, et al., “Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer,” Journal of Chemotherapy, vol. 20, pp. 632–639, 2008.
- J. M. Jurado, A. Sanchiz, B. Pajares, E. Perez, L. Alonso, and E. Alba, “Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer,” Clinical and Translational Oncology, vol. 10, pp. 583–586, 2008.
- O. Casanovas, D. J. Hicklin, G. Bergers, and D. Hanahan, “Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors,” Cancer Cell, vol. 8, no. 4, pp. 299–309, 2005.
- T. T. Batchelor, A. G. Sorensen, E. Di Tomaso et al., “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007.
- G. Bocci, S. Man, S. K. Green et al., “Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies,” Cancer Research, vol. 64, no. 18, pp. 6616–6625, 2004.